Microbial Fermentation APIs Market By Type (Antibiotics, Amino Acids, Vitamin, Nucleotide, Organic Acid, Alcohol, Biological Products, and Hormone), By Application (Hospitals, Research & Academic Laboratories, and Pharmaceutical & Biotechnology Companies), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI117219 | Publish Date: April 2024 | No. of Pages: 180

Global Microbial Fermentation APIS Market Companies

  • Merck & Co, Inc.
  • Ajinomoto Inc.
  • HGPF
  • Huaxing Co, Ltd.
  • North China Pharmaceutical Inc.
  • Henan Topfond Pharmaceutical Co, Ltd.
  • DSM B.V
  • Tianyao Pharmacutical Co, Ltd.
  • CSPC Pharmaceutical Group Ltd.

Recent News:

  • BIOVECTRA announced in October 2022 that it would be utilizing single-use microbial fermentation technology to expand its manufacturing capacity. This action will improve capacity utilization, turnaround times, and customer flexibility. The purpose of single-use sterile fermenters is to make mixing, chilling, and oxygen transfer easier. In terms of batch segregation and cross-contamination hazards, they provide a unique alternative and a notable benefit over stainless steel fermenters.
  • Science and technology startup Antheia revealed in November 2022 that they are working on next-generation plant-inspired medications, which will involve fermenting complex active pharmaceutical ingredients (APIs) that were previously only available from botanical sources. Antheia wants to make drug and essential medicine supply chains more robust and sustainable by developing a route for fermentation-based API production.